Respondents broadly supported clearer guidance on how evidence on health inequalities should be presented and how impacts are ...

Connecting 80+ EHS experts in pharma and biopharma on the West coast, this year's meeting will address the challenges of ...

For well over a decade, scientists, health leaders, and global organisations have sounded the alarm on antimicrobial ...

The deal for CARGO, which remains relatively well funded despite its troubles, comes with a contingent value right (CVR) that ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...

Despite a certain amount of upheaval at the FDA, the agency has continued to keep up with its scheduled approvals and clearances. At BIO 2025, editor-in-chief Jonah Comstock sat down with Mursla Bio ...

KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...

On the forefront of healthcare change, turning innovative science into value for patients: Astellas at ASCO 2025 At this year ...

Also cited in the complaint (PDF) are FDA Commissioner Marty Makary, NIH Director Jay Bhattacharya, who appeared alongside ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...